200 related articles for article (PubMed ID: 11384232)
21. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress.
Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Bonache MC; De Castro S
Curr Pharm Des; 2006; 12(15):1895-907. PubMed ID: 16724955
[TBL] [Abstract][Full Text] [Related]
22. Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HIV-1 RT. Studies in the linker and ddN region.
Velázquez S; Tuñón V; Jimeno ML; Pérez-Pérez MJ; San-Félix A; Chamorro C; Lobatón E; Esteban-Gamboa A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides; 1999; 18(4-5):1029-30. PubMed ID: 10432737
[TBL] [Abstract][Full Text] [Related]
23. 4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family.
Lobatón E; Velázquez S; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):711-4. PubMed ID: 11563098
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
Das K; Bauman JD; Rim AS; Dharia C; Clark AD; Camarasa MJ; Balzarini J; Arnold E
J Med Chem; 2011 Apr; 54(8):2727-37. PubMed ID: 21446702
[TBL] [Abstract][Full Text] [Related]
25. Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Van Laethem K; Schmit JC; Pelemans H; Balzarini J; Witvrouw M; Pérez-Pérez MJ; Camarasa MJ; Esnouf RM; Aquaro S; Cenci A; Perno CF; Hermans P; Sprecher S; Ruiz L; Clotet B; Van Wijngaerden E; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
AIDS Res Hum Retroviruses; 2000 Jun; 16(9):825-33. PubMed ID: 10875608
[TBL] [Abstract][Full Text] [Related]
26. Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-, 5-, and 6-substituted pyrimidine analogues.
San-Félix A; Velázquez S; Pérez-Pérez MJ; Balzarini J; De Clercq E; Camarasa MJ
J Med Chem; 1994 Feb; 37(4):453-60. PubMed ID: 7509877
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
[TBL] [Abstract][Full Text] [Related]
28. TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.
Pérez-Pérez MJ; San-Félix A; Balzarini J; De Clercq E; Camarasa MJ
J Med Chem; 1992 Aug; 35(16):2988-95. PubMed ID: 1501224
[TBL] [Abstract][Full Text] [Related]
29. Unusual lability of 5'-O-tert-butyldimethylsilyl group on 4''-acyl TSAO derivatives.
de Castro S; Pérez-Pérez MJ; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):959-61. PubMed ID: 14565321
[No Abstract] [Full Text] [Related]
30. Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
Moura M; Josse S; Nguyen Van Nhien A; Fournier C; Duverlie G; Castelain S; Soriano E; Marco-Contelles J; Balzarini J; Postel D
Eur J Med Chem; 2011 Oct; 46(10):5046-56. PubMed ID: 21880398
[TBL] [Abstract][Full Text] [Related]
31. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
32. Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
Velázquez S; Lobatón E; De Clercq E; Koontz DL; Mellors JW; Balzarini J; Camarasa MJ
J Med Chem; 2004 Jun; 47(13):3418-26. PubMed ID: 15189038
[TBL] [Abstract][Full Text] [Related]
33. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization.
Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ
Antivir Chem Chemother; 2005; 16(3):147-53. PubMed ID: 16004078
[TBL] [Abstract][Full Text] [Related]
34. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Chamorro C; Camarasa MJ; Pérez-Pérez MJ; de Clercq E; Balzarini J; San Félix A
Antivir Chem Chemother; 1998 Sep; 9(5):413-22. PubMed ID: 9875394
[TBL] [Abstract][Full Text] [Related]
35. TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl 3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) purine and purine-modified nucleosides.
Velázquez S; San-Félix A; Pérez-Pérez MJ; Balzarini J; De Clercq E; Camarasa MJ
J Med Chem; 1993 Oct; 36(22):3230-9. PubMed ID: 8230113
[TBL] [Abstract][Full Text] [Related]
36. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
Nguyen Van Nhien A; Tomassi C; Len C; Marco-Contelles JL; Balzarini J; Pannecouque C; De Clercq E; Postel D
J Med Chem; 2005 Jun; 48(13):4276-84. PubMed ID: 15974581
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase.
Velázquez S; Alvarez R; San-Félix A; Jimeno ML; De Clercq E; Balzarini J; Camarasa MJ
J Med Chem; 1995 May; 38(10):1641-9. PubMed ID: 7538589
[TBL] [Abstract][Full Text] [Related]
38. Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation.
Bonache MC; Quesada E; Sheen CW; Balzarini J; Sluis-Cremer N; Pérez-Pérez MJ; Camarasa MJ; San-Félix A
Nucleosides Nucleotides Nucleic Acids; 2008 Apr; 27(4):351-67. PubMed ID: 18404570
[TBL] [Abstract][Full Text] [Related]
39. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3-N- methyl-thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dio xide).
Balzarini J; Naesens L; Bohman C; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E
Biochem Pharmacol; 1993 Jul; 46(1):69-77. PubMed ID: 8102234
[TBL] [Abstract][Full Text] [Related]
40. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
Boyer PL; Ding J; Arnold E; Hughes SH
Antimicrob Agents Chemother; 1994 Sep; 38(9):1909-14. PubMed ID: 7529011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
